CLINICAL TRIALS PROFILE FOR ERGOLOID MESYLATES
✉ Email this page to a colleague
All Clinical Trials for ERGOLOID MESYLATES
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01475578 ↗ | Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency) | Completed | Sinphar Pharmaceutical Co., Ltd | Phase 2 | 2002-03-01 | The objectives of this phase II study of STA-1 capsule was to make preliminary evaluation on clinical efficacy and safety of STA-1 capsule in order that based on the dosage and study structure planned in this project, the dosage and study structure of phase III study can be confirmed. |
NCT05030129 ↗ | Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Syndrome | Not yet recruiting | Elizabeth Berry-Kravis | Phase 2 | 2021-09-15 | A preliminary assessment of the safety, tolerability and efficacy of Ergoloid mesylates (EM) and 5-hydroxytryptophan (5-HTP) and the combination (EM + 5-HTP) compared to placebo in males aged 18-45 years old with Fragile X Syndrome. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ERGOLOID MESYLATES
Condition Name
Clinical Trial Locations for ERGOLOID MESYLATES
Clinical Trial Progress for ERGOLOID MESYLATES
Clinical Trial Phase
Clinical Trial Sponsors for ERGOLOID MESYLATES
Sponsor Name